{
  "authors": [
    {
      "author": "Hisashi Tanaka"
    },
    {
      "author": "Akihito Hayashi"
    },
    {
      "author": "Takeshi Morimoto"
    },
    {
      "author": "Kageaki Taima"
    },
    {
      "author": "Yoshihito Tanaka"
    },
    {
      "author": "Michiko Shimada"
    },
    {
      "author": "Akira Kurose"
    },
    {
      "author": "Shingo Takanashi"
    },
    {
      "author": "Ken Okumura"
    }
  ],
  "doi": "10.1186/1471-2407-12-558",
  "publication_date": "2012-11-28",
  "id": "EN116735",
  "url": "https://pubmed.ncbi.nlm.nih.gov/23181703",
  "source": "BMC cancer",
  "source_url": "",
  "licence": "CC BY",
  "language": "en",
  "type": "pubmed",
  "description": "",
  "text": "We report a 39-year-old patient diagnosed as adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene. We treated this patient with erlotinib as the third line therapy, but no clinical benefit was obtained."
}